TheraPsil announced an MDMA-Assisted Psychotherapy Training Program for healthcare professionals. The pilot phase was expected to begin in early 2024 and to build on completion of TheraPsil’s Fundamentals of Psilocybin-Assisted Psychotherapy training.
Therapsil
English
TheraPsil announced a new MDMA-Assisted Psychotherapy Training Program as part of its work to expand access to psychedelic-assisted psychotherapy in Canada. The program was described as a response to growing demand for training and treatment in MDMA-assisted psychotherapy for trauma survivors. Curriculum development and rollout were to be led by Dr. Ingrid Pacey, a TheraPsil trainer who served as Principal Investigator of the MAPS Phase 2 MDMA trial in Vancouver. The organization said the pilot phase would launch in early 2024. The training was intended for practitioners who had successfully completed the didactic component of TheraPsil’s Fundamentals of Psilocybin-Assisted Psychotherapy training program. TheraPsil also noted that the expansion would support access to legal MDMA-assisted psychotherapy through Health Canada’s Special Access Program.
Healthcare professionals and practitioners who have completed the didactic component of TheraPsil’s Fundamentals of Psilocybin-Assisted Psychotherapy training program.
Successful completion of the didactic component of TheraPsil’s Fundamentals of Psilocybin-Assisted Psychotherapy training program.
TheraPsil is a Canadian grassroots nonprofit advancing compassionate, legal access to psilocybin-assisted psychotherapy through clinician training, patient advocacy, and legal reform, having trained over 700 healthcare professionals since 2019. The organization assists Canadians in navigating Health Canada's Special Access Program, supports patient-rights litigation in Federal Court, and operates the PsilWell community-funded clinical trial exploring psilocybin-assisted therapy for general wellbeing.
By Double Blind
This article examines how ketamine clinics may serve as a model for future legal psychedelic therapy, especially for MDMA and psilocybin. It compares clinic models, regulation, and the role of psychotherapy in treatment delivery.
By CIIS
A 12-month certificate in psychedelic-assisted therapies and research offered by CIIS. The program includes hybrid or online study and covers clinical competencies, research, cultural context, and ethical practice.
Next cohort: Jun 1, 2026
By Phoenix Academy
Online course in clinical psychedelic therapy covering preparation, dosing, safety, integration, and work with co-therapists and clients. Includes videos, interactive content, quizzes, and course documents.